Idarucizumab
Praxbind (idarucizumab) is an antibody pharmaceutical. Idarucizumab was first approved as Praxbind on 2015-10-16. It has been approved in Europe to treat hemorrhage.
| Trade Name | Praxbind |
|---|---|
| Common Name | Idarucizumab |
| Indication | hemorrhage |
| Drug Class | Monoclonal antibodies: humanized, cardiovascular indications |
